International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of all issues and individual articles published by the Journal since 1997.

LEARN MORE

PostScription: The Home Field Advantage

Author(s): Cabaleiro Joe

Issue: Jan/Feb 2016 - Volume 20, Number 1
View All Articles in Issue

Page(s): 86-87

PostScription: The Home Field Advantage Page 1

PostScription: The Home Field Advantage Page 2

Download in electronic PDF format for $75

Abstract:

Related Keywords: non-U.S. compounders, U.S. Food and Drug Administration, FDA, quality control, regulation

Related Categories: BUSINESS, LEGAL, QUALITY CONTROL

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
PostScription: The Home Field Advantage Cabaleiro Joe	Jan/Feb 2016 Pg. 86-87
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Kupiec Tom, Kemp Jesse	Jul/Aug 2007 Pg. 326-327
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1 Martin Matt	Sep/Oct 2018 Pg. 401-404
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Documentation: Records and Reports Akers Michael J	Sep/Oct 2017 Pg. 373-380
The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists Parks Kenneth Chase, Bernard Brian, Cogdill Christopher Blake	Sep/Oct 2015 Pg. 377-380
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1 Allen Loyd V Jr	Jul/Aug 2007 Pg. 350-351
Quality Control Analytical Methods: A Summarized Discussion of Current Good Manufacturing Practice Regulations Allen Loyd V Jr	May/Jun 2013 Pg. 210-219
U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Miller David G	Jan/Feb 2014 Pg. 35-36
Applying Quality of Design Concepts to Pharmacy Compounding Timko Robert J	Nov/Dec 2015 Pg. 453-463
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
Return to Top